Biopharma has finally begun catching up with the overall stock market, if the positive returns shown by the top three exchange traded funds (ETFs) since the spring are any indication. Over the past six months, shares of the top three biopharma ETFs have jumped well into double digits. The top biotech-focused ETF with $6.562 billion…
WASHINGTON (AP) — Naturepedic, a mattress and furniture company based outside Cleveland, has been planning to introduce an upscale upholstered headboard late this year or early in 2026. But President Donald Trump has thrown those plans into disarray. On Thursday night, the president announced on social media that he was slapping a 30% tax on…
Shares of some big drugmakers jumped ahead of broader indexes Friday as Wall Street started sorting out President Donald Trump’s latest tariff announcement. The president said late Thursday that he would place 100% import taxes on pharmaceuticals starting Oct. 1, but those tariffs would not apply to companies building U.S. manufacturing plants. He defined that…
Technological dominance was once synonymous with proprietary innovations. But recent history suggests differently: true disruption comes from making technology cheap, accessible and inescapable. China rejects the traditional high-cost, high-margin model of innovation. While foundational artificial intelligence (AI) and biotechnological breakthroughs still largely originate in the United States, China excels at rapidly scaling up and optimising…
We recently compiled a list of the Retirement Stock Portfolio: 10 Healthcare Stocks to Buy. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other healthcare stocks. Healthcare stocks are widely considered a cornerstone of a retirement portfolio due to their resilience, long-term growth potential,…
We recently published an article titled Jim Cramer Discusses These 18 Stocks & President Trump’s $500 Billion AI Plan. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other stocks Jim Cramer recently discussed. In his latest appearance on CNBC’s Squawk on the Street, Jim…